Latest news

Debiopharm and Aurigene enter into an Agreement to identify and develop selective compounds for immuno-oncology targets

Moapar® 3-months approved for the lowering of testosterone to castrate serum levels for control of sexual drive in adult men

The Debiopharm Group and Sigma-Tau sign R&D and commercial agreement for Istaroxime in acute heart failure syndromes

The Debiopharm Group to initiate confirmatory phase III trial for Sanvar® in esophageal variceal bleeding

Debiopharm and TcLand sign R&D and exclusive license option for the development of sc28AT autoimmune diseases and transplantation

Debiopharm et la Haute Ecole Valaisanne collaborent pour développer les médicaments de demain

Debiopharm presents phase I monthly implant and phase II daily oral results of ZT-1 for Alzheimer´s disease

Debiopharm S.A. presented results of a double-blind placebo-controlled study on first-in-class Debio-025 in HIV-1-infected subjects

Debiopharm and Dyax Corp. restructure development agreement for Depelestat (EPI-hNE4 or DX-890) in pulmonary disorders